OBJECTIVE: To assess the uptake of and adherence to nevirapine to prevent mother-to-child HIV transmission among women of unknown HIV serostatus presenting in labor. We also assessed preliminary efficacy of the approach. DESIGN: Women of unknown HIV serostatus presenting in labor were offered single-dose nevirapine in a prospective cohort study. Two additional contemporaneous comparison populations were also studied. METHODS: We measured uptake by counting the number of women that accepted enrollment when offered. We measured adherence with cord blood nevirapine assay. We measured preliminary efficacy with HIV DNA polymerase chain reaction of infant blood spots at 4-6 weeks of life. RESULTS: Of 1591 women approached in labor, 634 (40%) took up the intervention and received nevirapine, of whom 185 (29%) were HIV infected. Of 179 cord blood specimens from HIV-exposed infants that could be evaluated, 178 (99.4%) had nevirapine detected. This was higher than the 73 of 98 (74%) adherence rate observed in a comparison cohort in which women self-administered nevirapine before presenting to the labor ward (P < 0.001). Of 145 available infant specimens, 17 (11.7%) showed evidence of infection at 4-6 weeks, compared with 12 of 60 (20%) infants born immediately prior to study commencement whose HIV-infected mothers did not receive nevirapine (P < 0.05). CONCLUSIONS: Nevirapine without HIV testing upon presentation in labor was accepted by two-fifths of women. Because therapy is directly observed, adherence is nearly perfect. Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV.
OBJECTIVE: To assess the uptake of and adherence to nevirapine to prevent mother-to-child HIV transmission among women of unknown HIV serostatus presenting in labor. We also assessed preliminary efficacy of the approach. DESIGN:Women of unknown HIV serostatus presenting in labor were offered single-dose nevirapine in a prospective cohort study. Two additional contemporaneous comparison populations were also studied. METHODS: We measured uptake by counting the number of women that accepted enrollment when offered. We measured adherence with cord blood nevirapine assay. We measured preliminary efficacy with HIV DNA polymerase chain reaction of infant blood spots at 4-6 weeks of life. RESULTS: Of 1591 women approached in labor, 634 (40%) took up the intervention and received nevirapine, of whom 185 (29%) were HIV infected. Of 179 cord blood specimens from HIV-exposed infants that could be evaluated, 178 (99.4%) had nevirapine detected. This was higher than the 73 of 98 (74%) adherence rate observed in a comparison cohort in which women self-administered nevirapine before presenting to the labor ward (P < 0.001). Of 145 available infant specimens, 17 (11.7%) showed evidence of infection at 4-6 weeks, compared with 12 of 60 (20%) infants born immediately prior to study commencement whose HIV-infected mothers did not receive nevirapine (P < 0.05). CONCLUSIONS:Nevirapine without HIV testing upon presentation in labor was accepted by two-fifths of women. Because therapy is directly observed, adherence is nearly perfect. Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV.
Authors: K M De Cock; M G Fowler; E Mercier; I de Vincenzi; J Saba; E Hoff; D J Alnwick; M Rogers; N Shaffer Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: Jeffrey S A Stringer; Moses Sinkala; Julia P Stout; Robert L Goldenberg; Edward P Acosta; Victoria Chapman; Rosemary Kumwenda-Phiri; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2003-04-15 Impact factor: 3.731
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: J S Stringer; D J Rouse; S H Vermund; R L Goldenberg; M Sinkala; A A Stinnett Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: Jeffrey S A Stringer; Moses Sinkala; Victoria Chapman; Edward P Acosta; Grace M Aldrovandi; Victor Mudenda; Julia P Stout; Robert L Goldenberg; Rosemary Kumwenda; Sten H Vermund Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro Journal: Lancet Date: 2003-09-13 Impact factor: 79.321
Authors: Elizabeth M Stringer; Moses Sinkala; Jeffrey S Stringer; Elizabeth Mzyece; Ida Makuka; Robert L Goldenberg; Pascal Kwape; Martha Chilufya; Sten H Vermund Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Cristina M Marazzi; Paola Germano; Giuseppe Liotta; Giovanni Guidotti; Sandra Loureiro; Aurelio da Cruz Gomes; Maria C Valls Blazquez; Pasquale Narciso; Carlo F Perno; Sandro Mancinelli; Annamaria Doro Altan; Karin Nielsen-Saines; Leonardo Palombi Journal: Eur J Pediatr Date: 2007-01-18 Impact factor: 3.183
Authors: Jeffrey Sa Stringer; Moses Sinkala; Courtney C Maclean; Jens Levy; Chipepo Kankasa; Alain Degroot; Elizabeth M Stringer; Edward P Acosta; Robert L Goldenberg; Sten H Vermund Journal: AIDS Date: 2005-08-12 Impact factor: 4.177
Authors: Yolan Banda; Victoria Chapman; Robert L Goldenberg; Benjamin H Chi; Sten H Vermund; Jeffrey S A Stringer Journal: Trop Med Int Health Date: 2007-07 Impact factor: 2.622